Vetter, a global CDMO, is expanding capacities and services for the provision of clinical trial materials with the additional equipment for aseptic production and the expansion of storage capacities at the clinical site in Rankweil, Austria. 
 
Vetter has successfully completed the first year of production in Rankweil and is preparing to further increase production capacities and capabilities on site. With 14 batches already filled in the first quarter of 2023, the number of batches produced in total at the site in 2022 has already been surpassed. The further expansion of the site will make it possible to more than double the production volume by the end of the year. 

 
The use of a second autoclave and washing machine for material preparation will significantly increase cleanroom utilization. Vetter has doubled the capacity for cold storage by purchasing additional freezers, and is also expanding its service offering with the implementation of an isolator, so powdered substances can now also be processed in Rankweil. Further options for primary packaging materials expand the portfolio for clinical filling. 

 
Dr. Claus Feussner, Senior Vice President, Vetter Development Service, said, “In addition to our existing clinical manufacturing facility in Chicago, Rankweil has established itself in a very short time as a strategically important location for us and our partners. Customer service, efficient processes and our high quality standard are the focus.”